Goldman Sachs
ANIX icon

Goldman Sachs’s Anixa Biosciences ANIX Stock Holding History

Goldman Sachs’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,501
Closed -$64K – 5635
2024
Q1 		$64K Buy
+20,501
New +$81.8K ﹤0.01% 5298
2022
Q2 		– Sell
-13,080
Closed -$36K – 6437
2022
Q1 		$36K Sell
13,080
-3,399
-21% -$9.97K ﹤0.01% 6322
2021
Q4 		$49K Buy
+16,479
New +$66.6K ﹤0.01% 6272
2018
Q2 		– Sell
-27,479
Closed -$106K – 5634
2018
Q1 		$106K Buy
+27,479
New +$106K ﹤0.01% 5264

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs's ANIX Position: Q2 2024 in Review

Goldman Sachs sold out of Anixa Biosciences (ANIX) in Q2 2024, closing a stake of 20,501 shares — an estimated $64K sold.

Goldman Sachs first reported a position in ANIX in Q1 2018 and held it in 4 quarters. The position peaked at $106K in Q1 2018. 53 funds tracked by Wall St. Rank hold ANIX as of Q2 2024.

  • Goldman Sachs reported no remaining Anixa Biosciences position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 20,501 Anixa Biosciences shares in Q2 2024, an estimated $64K.
  • Goldman Sachs first reported a position in Anixa Biosciences in Q1 2018 and held it in 4 quarters.
  • Goldman Sachs's Anixa Biosciences position peaked at $106K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.